Cargando…
Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach
BACKGROUND: The only potentially curative therapy for myelodysplastic syndrome is allogeneic hematopoietic cell transplant; unfortunately, there is a high relapse rate. The objective of this study was to perform a detailed clinicopathologic study of patients with relapsed myeloid neoplasm following...
Autores principales: | Courville, Elizabeth L., Griffith, Megan, Ustun, Celalettin, Yohe, Sophia, Warlick, Erica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746015/ https://www.ncbi.nlm.nih.gov/pubmed/29299024 http://dx.doi.org/10.1186/s12907-017-0066-8 |
Ejemplares similares
-
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome
por: Dillon, Laura W., et al.
Publicado: (2021) -
Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
por: McCormack, Steven E, et al.
Publicado: (2010) -
Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
por: Choi, Eun-Ji, et al.
Publicado: (2018) -
Adenomyosis: Difficult to Diagnose, and Difficult to Treat
por: Wood, C.
Publicado: (2001) -
Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling
por: Oltvai, Zoltán N., et al.
Publicado: (2021)